Aaron N. Hata

Oncology

149 13th St
Charlestown, MA 02129

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

Oxidized protein states define metastatic fitness in lung cancer.

Oxidized protein states define metastatic fitness in lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 29, 2026

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition.

Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASG12C suppresses PI3Kα and leads to potent tumor inhibition.

Journal: bioRxiv : the preprint server for biology

Published: May 07, 2026

ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity.

ApoFLARE: a luminescent reporter for direct quantification of APOBEC3A editing activity.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

Journal: Oncogene

Published: March 05, 2026

Targeted therapy-induced chromosomal instability dictates mitotic dependency on Aurora Kinase A.

Targeted therapy-induced chromosomal instability dictates mitotic dependency on Aurora Kinase A.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Systematic Targeting of Protein Complexes with Molecular COUPLrs.

Systematic Targeting of Protein Complexes with Molecular COUPLrs.

Journal: Cancer discovery

Published: January 05, 2026

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Journal: Signal transduction and targeted therapy

Published: September 27, 2025

Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung Cancer.

Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung Cancer.

Journal: bioRxiv : the preprint server for biology

Published: August 12, 2025

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction.

Journal: Science (New York, N.Y.)

Published: June 12, 2025

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Journal: Cancer research

Published: April 28, 2025

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer.

Journal: Oncogene

Published: April 14, 2025

Showing 1-12 of 109

Last Updated: 09/26/2026